Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
about
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cellsMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasEGFR Signaling in Liver DiseasesInteractions between Myc and Mediators of Inflammation in Chronic Liver DiseasesThe significance of genetics for cholangiocarcinoma developmentIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesGenetic profiling of intrahepatic cholangiocarcinomaThe role of suppressors of cytokine signalling in human neoplasmsMonoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven eventsTargeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinomaDNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation statusInvestigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing dataPhosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1.TLR4 promotes Cryptosporidium parvum clearance in a mouse model of biliary cryptosporidiosis.DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.Recent advances in the regulation of cholangiocarcinoma growthHDAC6 inhibition restores ciliary expression and decreases tumor growthRelationship between methylation and colonic inflammation in inflammatory bowel disease.MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytesCholangiocarcinoma: new insights into disease pathogenesis and biology.Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells.Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupSilencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switchDramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3.IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancerTumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growthMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancers.JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction.Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 promotes cell proliferation and migration by upregulating DNMT1 via STAT3 activationDNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: evidence from a clinical cohort studyChronic inflammation and immunologic-based constraints in malignant disease.A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancerWhite blood cell global methylation and IL-6 promoter methylation in association with diet and lifestyle risk factors in a cancer-free population.The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cellsTranscriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasisIntegrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
P2860
Q24629061-AE0260D6-83B3-4367-AB7F-204962AC3767Q24669579-563AF9DD-CEF1-4004-99F2-5539DDE4A907Q26771265-0B5D3424-709C-4150-8A09-19F5C7A61CB4Q26778328-2E3BD571-CB53-443D-AD47-D611955E8DEDQ26865749-60545154-EF59-4213-A8E4-CD4732E40FE6Q27002547-DE9F22D9-6585-4E1F-801C-9B4306C40AEEQ27005787-E1D6DBFC-DF9B-41EF-8D63-3E298A2C4510Q27026783-8FE0AE39-BDDA-4A94-95C1-8768781C5F3FQ28273377-BA910889-C3CF-4BE1-908A-058AE466B6D4Q28476545-4C5D071A-2FED-4754-AD73-4D8F46EE82BAQ28544885-239F078E-3F17-45AF-9FAD-D5278D71732AQ28597874-37D06013-D580-4FE2-AD43-EABEDD0CF2ABQ30425294-0CD1F2D2-84B5-4A74-A2C5-D3742AD15CF7Q30430381-BECD3CAA-9007-413A-8CC1-1D437AF780A8Q30436675-D4C2DDAC-48DD-4178-B051-8479BA5BE4D1Q33994814-F24464A0-4E9A-4ECD-89A6-8151A206F83CQ34035361-F6FB08CC-5220-4BD5-B019-4EA13A88B114Q34036817-65FAA4AE-6343-4F33-8127-BAD848007330Q34097997-3CF2B3BD-4AB8-492A-B53F-CF341A32A010Q34194655-556BE34E-C60B-44AC-AE07-ADDFD6C848EFQ34196062-6023380D-786C-42FF-AAEC-D1A08CD945ADQ34225158-913B74F6-5EE2-4D0D-A8CD-6A929CC34869Q34460281-00C766C3-AF45-45A6-9E7E-917DFCEBD4B2Q34550326-AB5CD2B6-DFB0-4E2A-8045-1E8806AFAE9EQ34648030-7CA9D553-055F-4700-BAA5-14A4459CDE74Q34687041-6CA7A6C8-B06D-483D-BA7F-3018781C2427Q34700730-CDB2D5FC-2F88-4F69-80C3-152316A18221Q34811043-828BC8B1-746A-4BA3-950E-AB6466E298ECQ35023456-7F4F0447-DC91-4766-80A1-0A67FBC47E7CQ35109010-4A64A38E-7F7C-4BDC-B388-562C7EC4E060Q35133354-BA926493-F0AC-420C-85E1-B8ECFCCC4912Q35224793-C69D74D2-10FC-4A6F-B9CF-3B06743D1CE5Q35575974-BBB1D87F-2EE2-49B0-84DB-C0EDA8431855Q35620650-00651209-4A3C-4176-8E32-DABBDE5AE370Q35820533-76B695A0-067D-4122-AD01-23768E1B222AQ36042724-C5092481-23DD-4E4D-8B47-F390DF7E17F6Q36100989-8EFD52AF-1C67-466A-B8DB-2A8C3550DD1AQ36407783-DEFC5A6F-86C2-40DA-8154-ACA2F0196488Q36549751-5630D172-8EAE-4856-AD21-072058763D7CQ36759538-CB6ACF61-0447-45A0-A617-706D968D1B5E
P2860
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Interleukin-6 contributes to g ...... thylation and gene expression.
@en
type
label
Interleukin-6 contributes to g ...... thylation and gene expression.
@en
prefLabel
Interleukin-6 contributes to g ...... thylation and gene expression.
@en
P2093
P1433
P1476
Interleukin-6 contributes to g ...... thylation and gene expression.
@en
P2093
Fanyin Meng
Hania Wehbe
Janna Mize-Berge
Roger Henson
Tushar Patel
P304
10517-10524
P356
10.1158/0008-5472.CAN-06-2130
P407
P577
2006-11-01T00:00:00Z